PLUS1
0.034
-0.008 (-19.05%)
-0.008 (-19.05%)
Upgrade to Real-Time
Market Open
Best deals to access real time data! |
|
Small Cap Basic
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Boston Therapeutics Inc (PK) | BTHE | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.008 | -19.05% | 0.034 | 14:10:39 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.038 | 0.034 | 0.038 | 0.042 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 0.0321 | 0.042 | 0.0099 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5 | 138,090 | $ 0.035599 | $ 4,916 | - | 0.0055 - 0.067 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:29:21 | 27,500 | $ 0.034 | USD |
Boston Therapeutics (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 31.18M | 916.91M | 43.38M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 6.38k | $ - | 0.00% | - | - |
Boston Therapeutics (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/02/2021 | 17:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 12/17/2020 | 15:26 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/30/2020 | 12:44 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 6/08/2020 | 15:28 | Edgar (US Regulatory) | Annual Report (10-k) |
| 5/15/2020 | 16:56 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/15/2020 | 16:33 | Edgar (US Regulatory) | Amended Notification That Annual Report Will Be Submitted.. |
| 5/11/2020 | 17:15 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BTHE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0436 | 0.06 | 0.034 | 0.038996 | 187,128 | -0.0096 | -22.02% |
| 1 Month | 0.0475 | 0.06 | 0.017 | 0.0368373 | 218,137 | -0.0135 | -28.42% |
| 3 Months | 0.007 | 0.067 | 0.0055 | 0.0250689 | 203,430 | 0.027 | 385.71% |
| 6 Months | 0.0135 | 0.067 | 0.0055 | 0.0228014 | 138,702 | 0.0205 | 151.85% |
| 1 Year | 0.0171 | 0.067 | 0.0055 | 0.0210074 | 81,589 | 0.0169 | 98.83% |
| 3 Years | 0.10 | 0.105 | 0.0052 | 0.0282415 | 68,181 | -0.066 | -66.0% |
| 5 Years | 0.10 | 0.17 | 0.0052 | 0.0366567 | 55,731 | -0.066 | -66.0% |
Boston Therapeutics (PK) Description
| Boston Therapeutics, Inc. (OTCQB: BTHE), headquartered in Lawrence, MA, is a leader in the field of designing drugs using complex carbohydrates. The Company's product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including: BTI-320, a non-systemic chewable compound designed to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia; and SUGARDOWN(R), an OTC dietary supplement designed to lower post-meal sugar spike. More information on BTHE is available at www.bostonti.com. |
